发明名称 |
USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2 |
摘要 |
The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253. |
申请公布号 |
US2012251538(A1) |
申请公布日期 |
2012.10.04 |
申请号 |
US201013509068 |
申请日期 |
2010.11.12 |
申请人 |
HARDING THOMAS;KAVANAUGH MICHAEL W.;FIVE PRIME PHARMACEUTIALS, INC. |
发明人 |
HARDING THOMAS;KAVANAUGH MICHAEL W. |
分类号 |
A61K38/17;A61K39/395;A61P35/00 |
主分类号 |
A61K38/17 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|